News coverage about Dimension Therapeutics (NASDAQ:DMTX) has been trending somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.201804288926 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Dimension Therapeutics (DMTX) remained flat at $$5.95 during mid-day trading on Tuesday. Dimension Therapeutics has a 52 week low of $1.05 and a 52 week high of $6.10. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.33 and a current ratio of 2.01.
Dimension Therapeutics (NASDAQ:DMTX) last announced its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.20). The company had revenue of $4.48 million for the quarter. Dimension Therapeutics had a negative return on equity of 136.17% and a negative net margin of 336.65%. equities research analysts expect that Dimension Therapeutics will post -1.99 EPS for the current fiscal year.
Several research analysts have issued reports on the stock. Chardan Capital restated a “hold” rating on shares of Dimension Therapeutics in a report on Monday, August 14th. Canaccord Genuity lowered shares of Dimension Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $12.00 to $3.41 in a report on Wednesday, August 30th. Citigroup Inc. lowered shares of Dimension Therapeutics from a “neutral” rating to a “sell” rating and raised their price target for the stock from $3.41 to $5.50 in a report on Tuesday, September 19th. Wells Fargo & Company lowered shares of Dimension Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $9.00 to $6.00 in a report on Tuesday, October 3rd. Finally, ValuEngine upgraded shares of Dimension Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 30th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company’s stock. Dimension Therapeutics currently has an average rating of “Hold” and an average price target of $5.08.
About Dimension Therapeutics
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.